ProCE Banner Activity

Expanding the Treatment Landscape for Patients With Hemophilia A

Clinical Thought
With improved therapies, we can reduce the treatment burden of hemophilia A for patients. Here’s my take on how far we have come and where we are going.

Released: October 16, 2019

Expiration: October 14, 2020

No longer available for credit.

Share

Faculty

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Faculty Disclosure

Primary Author

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received consulting fees from CSL Behring, Freeline, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Shire/Takeda, Spark, and uniQure; fees for non-CME/CE services from Bioverativ and Genentech; and funds for research support from Genentech.